CABA-201
A chimeric antigen receptor (CAR) is a cellular receptor engineered to connect an extracellular targeting function with intracellular domains that activate the cytotoxic potential of T cells. CAR (Chimeric Antigen Receptor) T cells are T cells that have been engineered with additional receptors to identify specific proteins, called antigens, present on the surface of other cells. The Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach is designed to transiently, but fully, eliminate B cells, thus potentially enabling an “immune system reset.” CABA-201, is a fully human CD19-CAR T cell product being developed for use in autoimmune diseases.
Enroll in this clinical study
How is CABA-201 being studied in Lupus nephritis?
The safety and efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in subjects with active Systemic Lupus Erythematosus is being studied in this Phase 1/2, Open-label Study. The primary outcome is to evaluate the incidence of adverse events.
Eligibility Criteria
Age ≥18 and ≤65
For LN subjects only, active, biopsy-proven LN class III or IV, with or without the presence of class V, according to 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria
For non-renal SLE subjects only: Active, moderate to severe SLE